CA3043610A1 - Crystalline forms of a magl inhibitor - Google Patents
Crystalline forms of a magl inhibitor Download PDFInfo
- Publication number
- CA3043610A1 CA3043610A1 CA3043610A CA3043610A CA3043610A1 CA 3043610 A1 CA3043610 A1 CA 3043610A1 CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A CA3043610 A CA 3043610A CA 3043610 A1 CA3043610 A1 CA 3043610A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- crystalline form
- theta
- crystalline
- hexafluoropropan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423126P | 2016-11-16 | 2016-11-16 | |
| US62/423,126 | 2016-11-16 | ||
| PCT/US2017/061875 WO2018093953A1 (en) | 2016-11-16 | 2017-11-15 | Crystalline forms of a magl inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3043610A1 true CA3043610A1 (en) | 2018-05-24 |
Family
ID=62145805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3043610A Pending CA3043610A1 (en) | 2016-11-16 | 2017-11-15 | Crystalline forms of a magl inhibitor |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| CN113413387A (zh) | 2015-05-11 | 2021-09-21 | H.隆德贝克有限公司 | 治疗炎症或神经性疼痛的方法 |
| US10899737B2 (en) | 2016-09-19 | 2021-01-26 | Lundbeck La Jolla Research Center, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| UA124884C2 (uk) | 2016-11-16 | 2021-12-08 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Фармацевтичні склади |
| MA46866B1 (fr) | 2016-11-16 | 2021-11-30 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| DK3630744T3 (da) | 2017-05-23 | 2023-03-06 | H Lundbeck As | Pyrazol-magl-inhibitorer |
| JP7257387B2 (ja) | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| GEP20227443B (en) | 2018-05-15 | 2022-11-25 | H Lundbeck As | Magl inhibitors |
| MX2021000549A (es) * | 2018-07-19 | 2021-03-25 | Pfizer | Compuestos espiro heterociclicos como inhibidores de magl. |
| ES2986417T3 (es) | 2018-08-13 | 2024-11-11 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
| ES2955037T3 (es) | 2018-11-22 | 2023-11-28 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
| CA3125636A1 (en) * | 2019-01-25 | 2020-07-30 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| KR20220101095A (ko) * | 2019-11-15 | 2022-07-19 | 하. 룬드벡 아크티에셀스카브 | Magl 억제제의 결정형 |
| WO2021214550A1 (en) * | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| WO2023092079A1 (en) * | 2021-11-19 | 2023-05-25 | Bryant Cynthia W | Use of cannabinoid compounds to treat gastrointestinal disorders |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
| CN117665187B (zh) * | 2023-11-23 | 2024-08-16 | 宁波大红鹰药业股份有限公司 | 一种舒林酸中间体杂质的测定方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| HUP0302455A3 (en) | 2000-12-18 | 2005-05-30 | Novartis Ag | Combination pharmaceutical compositions containing amplodipine and benazepril and their use |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| ATE420644T1 (de) | 2002-02-20 | 2009-01-15 | Abbott Lab | Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1) |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| JP2008531509A (ja) | 2005-02-25 | 2008-08-14 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬品成分の改良された分散性を有する錠剤 |
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| EP1938804A1 (en) | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
| FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
| PE20141702A1 (es) | 2012-01-06 | 2014-11-19 | Abide Therapeutics Inc | Compuestos de carbamato y preparacion y uso de los mismos |
| CA2866302A1 (en) | 2012-03-19 | 2013-09-26 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| EP2844247A4 (en) | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
| US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
| JP6647592B2 (ja) | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
| US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
| WO2015164160A1 (en) * | 2014-04-21 | 2015-10-29 | Merck Sharp & Dohme Corp. | Pharmaceutical salts of an orexin receptor antagonist |
| US10093630B2 (en) * | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| JP2018513119A (ja) | 2015-03-18 | 2018-05-24 | アビデ セラピューティクス，インク． | ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法 |
| CN113413387A (zh) | 2015-05-11 | 2021-09-21 | H.隆德贝克有限公司 | 治疗炎症或神经性疼痛的方法 |
| US10463753B2 (en) * | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MA46866B1 (fr) | 2016-11-16 | 2021-11-30 | H Lundbeck As | Une forme cristalline d'un inhibiteur de magl |
| UA124884C2 (uk) | 2016-11-16 | 2021-12-08 | Лундбек Ла Джолла Ресеарч Центер, Інк. | Фармацевтичні склади |
-
2017
- 2017-11-15 MA MA46866A patent/MA46866B1/fr unknown
- 2017-11-15 CR CR20190242A patent/CR20190242A/es unknown
- 2017-11-15 DK DK17872429.0T patent/DK3541807T3/da active
- 2017-11-15 MY MYPI2019002687A patent/MY199386A/en unknown
- 2017-11-15 ES ES17872429T patent/ES2900016T3/es active Active
- 2017-11-15 ES ES21199077T patent/ES2966939T3/es active Active
- 2017-11-15 TN TNP/2019/000151A patent/TN2019000151A1/en unknown
- 2017-11-15 AU AU2017361257A patent/AU2017361257B2/en not_active Ceased
- 2017-11-15 EA EA201991086A patent/EA201991086A1/ru unknown
- 2017-11-15 PE PE2019001013A patent/PE20191239A1/es unknown
- 2017-11-15 MX MX2019005767A patent/MX389459B/es unknown
- 2017-11-15 LT LTEPPCT/US2017/061875T patent/LT3541807T/lt unknown
- 2017-11-15 EP EP17872429.0A patent/EP3541807B1/en active Active
- 2017-11-15 PL PL21199077.5T patent/PL3964503T3/pl unknown
- 2017-11-15 JO JOP/2019/0109A patent/JOP20190109B1/ar active
- 2017-11-15 RS RS20211501A patent/RS62665B1/sr unknown
- 2017-11-15 SM SM20210675T patent/SMT202100675T1/it unknown
- 2017-11-15 KR KR1020197017161A patent/KR102508739B1/ko active Active
- 2017-11-15 US US16/349,142 patent/US11142517B2/en active Active
- 2017-11-15 JP JP2019523672A patent/JP7042548B2/ja not_active Expired - Fee Related
- 2017-11-15 HU HUE21199077A patent/HUE064559T2/hu unknown
- 2017-11-15 PL PL17872429T patent/PL3541807T3/pl unknown
- 2017-11-15 SM SM20230494T patent/SMT202300494T1/it unknown
- 2017-11-15 EP EP21199077.5A patent/EP3964503B1/en active Active
- 2017-11-15 SI SI201730987T patent/SI3541807T1/sl unknown
- 2017-11-15 UA UAA201905624A patent/UA124585C2/uk unknown
- 2017-11-15 CN CN202210681321.7A patent/CN115093382A/zh active Pending
- 2017-11-15 HR HRP20211863TT patent/HRP20211863T1/hr unknown
- 2017-11-15 PT PT178724290T patent/PT3541807T/pt unknown
- 2017-11-15 RS RS20231263A patent/RS65016B1/sr unknown
- 2017-11-15 CA CA3043610A patent/CA3043610A1/en active Pending
- 2017-11-15 GE GEAP201715091A patent/GEP20237559B/en unknown
- 2017-11-15 CN CN201780083644.3A patent/CN110291083B/zh not_active Expired - Fee Related
- 2017-11-15 MA MA58133A patent/MA58133B1/fr unknown
- 2017-11-15 HU HUE17872429A patent/HUE056973T2/hu unknown
- 2017-11-15 BR BR112019010003A patent/BR112019010003A2/pt not_active Application Discontinuation
- 2017-11-15 WO PCT/US2017/061875 patent/WO2018093953A1/en not_active Ceased
- 2017-11-15 HR HRP20231697TT patent/HRP20231697T1/hr unknown
- 2017-11-15 GE GEAP202315091A patent/GEAP202315091A/en unknown
-
2019
- 2019-05-12 IL IL266548A patent/IL266548A/en unknown
- 2019-05-14 PH PH12019501068A patent/PH12019501068A1/en unknown
- 2019-05-16 DO DO2019000120A patent/DOP2019000120A/es unknown
- 2019-05-16 CL CL2019001340A patent/CL2019001340A1/es unknown
- 2019-05-16 CO CONC2019/0005045A patent/CO2019005045A2/es unknown
- 2019-05-16 NI NI201900053A patent/NI201900053A/es unknown
- 2019-05-16 EC ECSENADI201935171A patent/ECSP19035171A/es unknown
- 2019-05-16 MX MX2022000249A patent/MX2022000249A/es unknown
- 2019-05-17 ZA ZA2019/03093A patent/ZA201903093B/en unknown
-
2021
- 2021-09-08 US US17/469,535 patent/US11993588B2/en active Active
- 2021-12-13 CY CY20211101092T patent/CY1124870T1/el unknown
-
2022
- 2022-03-08 JP JP2022035398A patent/JP7350117B2/ja active Active
-
2024
- 2024-01-29 CY CY20241100067T patent/CY1126586T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993588B2 (en) | Crystalline forms of a MAGL inhibitor | |
| JP2025026857A (ja) | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 | |
| RS66922B1 (sr) | Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3 | |
| US9956201B2 (en) | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | |
| HK40069310A (en) | A crystalline form of a magl inhibitor | |
| HK40069310B (en) | A crystalline form of a magl inhibitor | |
| RU2799564C2 (ru) | Кристаллические формы ингибитора magl | |
| HK40009165A (en) | A crystalline form of a magl inhibitor | |
| HK40009165B (en) | A crystalline form of a magl inhibitor | |
| AU2018325267B2 (en) | Crystalline forms of compounds for preventing or treating sensory hair cell death | |
| EA041551B1 (ru) | Кристаллические формы ингибитора magl | |
| NZ753241B2 (en) | Crystalline forms of a magl inhibitor | |
| WO2026085383A1 (en) | Crystalline forms of an nlrp3 modulator | |
| EP4551576A1 (en) | Crystalline forms of a tyk2 inhibitor | |
| EP4551573A1 (en) | Crystalline forms of an s1p receptor modulator | |
| WO2017073738A1 (ja) | フェキソフェナジンを有効成分とする錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251111 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260107 |